cytarabine has been researched along with 5'-s-(2-aminoethyl)-n(6)-(4-nitrobenzyl)-5'-thioadenosine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brocklebank, AM; Cass, CE; Craik, JD; Jamieson, GP; McAdam, DP; Paterson, AR; Robins, MJ; Sawyer, WH; Snook, MB; Wiley, JS | 1 |
Brocklebank, AM; Buolamwini, JK; Jamieson, GP; Paterson, AR; Sawyer, WH; Snook, MB; Wiley, JS | 1 |
Belch, AR; Gati, WP; Larratt, LM; Paterson, AR; Turner, AR | 1 |
Gati, WP; Larratt, LM; Turner, AR | 1 |
4 other study(ies) available for cytarabine and 5'-s-(2-aminoethyl)-n(6)-(4-nitrobenzyl)-5'-thioadenosine
Article | Year |
---|---|
A new fluorescent probe for the equilibrative inhibitor-sensitive nucleoside transporter. 5'-S-(2-aminoethyl)-N6-(4-nitrobenzyl)-5'-thioadenosine (SAENTA)-chi 2-fluorescein.
Topics: Adenosine; Affinity Labels; Carrier Proteins; Cell Line; Cytarabine; Flow Cytometry; Fluorescent Dyes; Humans; Kinetics; Membrane Proteins; Molecular Structure; Nucleoside Transport Proteins; Spectrometry, Fluorescence; Thioinosine; Thionucleosides | 1991 |
Flow cytometric quantitation of nucleoside transporter sites on human leukemic cells.
Topics: Adenosine; Binding Sites; Carrier Proteins; Cell Line; Cytarabine; Fluoresceins; Humans; Leukemia, Myeloid; Ligands; Membrane Proteins; Nucleoside Transport Proteins; Purine Nucleosides; Thioinosine; Thionucleosides | 1993 |
Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein.
Topics: Acute Disease; Adenosine; Affinity Labels; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Death; Cytarabine; Flow Cytometry; Fluorescein; Fluoresceins; Humans; Leukemia; Nucleosides; Thionucleosides; Tumor Cells, Cultured | 1997 |
Cellular abundance of es nucleoside transporters and differential drug toxicity in myelodysplastic syndrome (MDS) bone marrow cell subpopulations.
Topics: Adenosine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Cells; Carrier Proteins; Cell Survival; Cytarabine; Flow Cytometry; Fluorescent Dyes; Humans; Ligands; Membrane Proteins; Methotrexate; Myelodysplastic Syndromes; Nucleoside Transport Proteins; Thionucleosides | 2001 |